Transgene Biotek began its journey as a private limited company in March 1990 and later transitioned into a public limited company in November of the same year. The company specializes in research, development, and production of various medical reagents, including both chemical and immuno-diagnostic reagents. These reagents serve the purpose of qualitatively and quantitatively estimating biochemical parameters and diagnosing diseases.
The company's product line is exported to several countries including Africa, Russia, China, Malaysia, and the Philippines. Recently, Transgene Biotek initiated a new project aimed at establishing a manufacturing facility in the Anrich Industrial Area, Bollaram, at a cost of Rs. 30 crore. Additionally, the company is actively working on four new plants focusing on oral delivery of proteins and peptides, DNA vaccines, fusion proteins, and biotherapeutics.
To fund this new project, Transgene Biotek is engaging in a preferential offer to Batterymarch Financial Management USA and other financial institutions.
The company's product line is exported to several countries including Africa, Russia, China, Malaysia, and the Philippines. Recently, Transgene Biotek initiated a new project aimed at establishing a manufacturing facility in the Anrich Industrial Area, Bollaram, at a cost of Rs. 30 crore. Additionally, the company is actively working on four new plants focusing on oral delivery of proteins and peptides, DNA vaccines, fusion proteins, and biotherapeutics.
To fund this new project, Transgene Biotek is engaging in a preferential offer to Batterymarch Financial Management USA and other financial institutions.
